$NBIX
NEUROCRINE BIOSCIENCES INC

2013 Q3 Form 10-Q Financial Statement

#000119312513416082 Filed on October 29, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2012 Q3
Revenue $729.0K $9.357M
YoY Change -92.21% -77.53%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.200M $3.300M
YoY Change -3.03% -13.16%
% of Gross Profit
Research & Development $9.490M $9.860M
YoY Change -3.75% 32.24%
% of Gross Profit
Depreciation & Amortization $200.0K $200.0K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $12.74M $13.32M
YoY Change -4.38% 18.98%
Operating Profit -$12.01M -$3.962M
YoY Change 203.03% -113.02%
Interest Expense $100.0K $100.0K
YoY Change 0.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $875.0K $884.0K
YoY Change -1.02% -6.16%
Pretax Income -$11.10M -$3.100M
YoY Change 258.06% -109.87%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.13M -$3.078M
YoY Change 261.63% -109.81%
Net Earnings / Revenue -1526.89% -32.9%
Basic Earnings Per Share -$0.17 -$0.05
Diluted Earnings Per Share -$0.17 -$0.05
COMMON SHARES
Basic Shares Outstanding 67.20M shares 66.34M shares
Diluted Shares Outstanding 67.20M shares 66.34M shares

Balance Sheet

Concept 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $156.9M $174.0M
YoY Change -9.83% 55.91%
Cash & Equivalents $34.89M $44.49M
Short-Term Investments $122.0M $129.5M
Other Short-Term Assets $2.232M $2.688M
YoY Change -16.96% 28.0%
Inventory
Prepaid Expenses
Receivables $100.0K $1.400M
Other Receivables $0.00 $0.00
Total Short-Term Assets $159.2M $178.0M
YoY Change -10.56% 30.8%
LONG-TERM ASSETS
Property, Plant & Equipment $1.739M $2.034M
YoY Change -14.5% 19.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $700.0K $8.900M
YoY Change -92.13% 74.51%
Other Assets $4.300M $4.300M
YoY Change 0.0% -29.51%
Total Long-Term Assets $6.749M $15.23M
YoY Change -55.69% 18.09%
TOTAL ASSETS
Total Short-Term Assets $159.2M $178.0M
Total Long-Term Assets $6.749M $15.23M
Total Assets $166.0M $193.3M
YoY Change -14.12% 29.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.097M $1.416M
YoY Change -22.53% 77.0%
Accrued Expenses $7.882M $8.130M
YoY Change -3.05% 6.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.32M $23.11M
YoY Change -42.37% -52.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $152.0K $152.0K
YoY Change 0.0% -99.64%
Total Long-Term Liabilities $152.0K $152.0K
YoY Change 0.0% -99.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.32M $23.11M
Total Long-Term Liabilities $152.0K $152.0K
Total Liabilities $36.68M $49.95M
YoY Change -26.57% -45.29%
SHAREHOLDERS EQUITY
Retained Earnings -$755.1M -$729.2M
YoY Change 3.56%
Common Stock $67.00K $66.00K
YoY Change 1.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $129.3M $143.3M
YoY Change
Total Liabilities & Shareholders Equity $166.0M $193.3M
YoY Change -14.12% 29.7%

Cashflow Statement

Concept 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$11.13M -$3.078M
YoY Change 261.63% -109.81%
Depreciation, Depletion And Amortization $200.0K $200.0K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$10.80M -$8.300M
YoY Change 30.12% -396.43%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$300.0K
YoY Change -66.67% -50.0%
Acquisitions
YoY Change
Other Investing Activities -$1.200M $11.00M
YoY Change -110.91% -40.22%
Cash From Investing Activities -$1.300M $10.70M
YoY Change -112.15% -39.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.700M 100.0K
YoY Change 2600.0% 0.0%
NET CHANGE
Cash From Operating Activities -10.80M -8.300M
Cash From Investing Activities -1.300M 10.70M
Cash From Financing Activities 2.700M 100.0K
Net Change In Cash -9.400M 2.500M
YoY Change -476.0% -87.92%
FREE CASH FLOW
Cash From Operating Activities -$10.80M -$8.300M
Capital Expenditures -$100.0K -$300.0K
Free Cash Flow -$10.70M -$8.000M
YoY Change 33.75% -335.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q2 nbix Cease Use Liability
CeaseUseLiability
2463000
CY2013Q2 nbix Cease Use Liability
CeaseUseLiability
3295000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44488000
CY2012Q3 nbix Cease Use Liability
CeaseUseLiability
2549000
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67343207 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67343207 shares
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13321000
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9000
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
884355000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1097000
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
152000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
129292000
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-755121000
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
730000
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7882000
CY2013Q3 us-gaap Liabilities
Liabilities
36675000
CY2013Q3 us-gaap Deferred Gain On Sale Of Property
DeferredGainOnSaleOfProperty
21700000
CY2013Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1955000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
67000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165967000
CY2013Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
122706000
CY2013Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4335000
CY2013Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
57373000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1739000
CY2013Q3 us-gaap Assets
Assets
165967000
CY2013Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34889000
CY2013Q3 us-gaap Short Term Investments
ShortTermInvestments
122022000
CY2013Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
57373000
CY2013Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2232000
CY2013Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
122697000
CY2013Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
75000
CY2013Q3 us-gaap Long Term Investments
LongTermInvestments
675000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Assets Current
AssetsCurrent
159218000
CY2013Q3 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2789000
CY2013Q3 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
409000
CY2013Q3 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
18458000
CY2013Q3 nbix Cease Use Liability
CeaseUseLiability
3198000
CY2013Q3 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3203000
CY2013Q3 nbix Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
27000
CY2013Q3 nbix Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
36000
CY2013Q3 nbix Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses Accumulated In Investments
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLossesAccumulatedInInvestments
36000
CY2013Q3 nbix Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses Accumulated In Investments
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments
CY2013Q3 nbix Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses Accumulated In Investments
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAccumulatedInInvestments
36000
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67343394 shares
CY2008Q4 us-gaap Deferred Gain On Sale Of Property
DeferredGainOnSaleOfProperty
39100000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50107000
CY2011Q4 nbix Cease Use Liability
CeaseUseLiability
2592000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66446888 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66446888 shares
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15646000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
873981000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
911000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
152000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
154372000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-719673000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2919000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8094000
CY2012Q4 us-gaap Liabilities
Liabilities
41607000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1840000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
66000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
195979000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
109741000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4335000
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
67492000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1900000
CY2012Q4 us-gaap Assets
Assets
195979000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63754000
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
109259000
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
67492000
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2162000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
109739000
CY2012Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
14089000
CY2012Q4 us-gaap Long Term Investments
LongTermInvestments
480000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
189264000
CY2012Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
3097000
CY2012Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
589000
CY2012Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
20872000
CY2012Q4 nbix Cease Use Liability
CeaseUseLiability
3686000
CY2012Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3133000
CY2012Q4 nbix Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
33000
CY2012Q4 nbix Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
35000
CY2012Q4 nbix Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses Accumulated In Investments
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLossesAccumulatedInInvestments
35000
CY2012Q4 nbix Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses Accumulated In Investments
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments
CY2012Q4 nbix Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses Accumulated In Investments
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAccumulatedInInvestments
35000
dei Trading Symbol
TradingSymbol
NBIX
dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0000914475
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
800000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66868000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18728000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
900000 shares
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15389000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30330000
nbix Potential Dilutive Securities That Could Be Included In Computation Of Earnings Per Share Amount
PotentialDilutiveSecuritiesThatCouldBeIncludedInComputationOfEarningsPerShareAmount
2200000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><i>Use of Estimates</i>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</font></p> </div>
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-26000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
354000
us-gaap Licenses Revenue
LicensesRevenue
2189000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
130379000
us-gaap Investment Income Net
InvestmentIncomeNet
317000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2382000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-13944000
us-gaap Revenues
Revenues
2189000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35455000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38148000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
38000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2700000
us-gaap Net Income Loss
NetIncomeLoss
-35448000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2108000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
115306000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
115000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10007000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5252000
us-gaap Share Based Compensation
ShareBasedCompensation
5123000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
515000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-28865000
us-gaap Operating Expenses
OperatingExpenses
40337000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2189000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5252000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
38000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5300000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5100000
nbix Deferred Gain Recognized
DeferredGainRecognized
2300000
nbix Lease Expiration Year
LeaseExpirationYear
2019
nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
2344000
nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
488000
nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-488000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1400000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65355000 shares
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
50000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26385000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2300000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
929000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
28000
us-gaap Licenses Revenue
LicensesRevenue
26255000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
106000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
139505000
us-gaap Investment Income Net
InvestmentIncomeNet
359000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
2301000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
684000
us-gaap Revenues
Revenues
31193000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4359000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7134000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
25000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2669000
us-gaap Net Income Loss
NetIncomeLoss
-4465000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2480000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
77789000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
238000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10126000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83414000
us-gaap Share Based Compensation
ShareBasedCompensation
4169000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
481000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5619000
us-gaap Operating Expenses
OperatingExpenses
38327000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-26256000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
83414000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
27000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
400000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4200000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-62648000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28066000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-16000
nbix Potential Dilutive Securities That Could Be Included In Computation Of Earnings Per Share Amount
PotentialDilutiveSecuritiesThatCouldBeIncludedInComputationOfEarningsPerShareAmount
1300000 shares
nbix Deferred Gain Recognized
DeferredGainRecognized
2300000
nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
2276000
nbix Sponsored Research And Development Revenue
SponsoredResearchAndDevelopmentRevenue
4938000
nbix Cease Use Expense
CeaseUseExpense
135000
nbix Deferred Rent Reversed
DeferredRentReversed
15000
nbix Increase Decrease In Cease Use Expense
IncreaseDecreaseInCeaseUseExpense
135000
nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
193000
nbix Impact Of Sublease On Cease Use Charges
ImpactOfSubleaseOnCeaseUseCharges
150000
nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-193000
CY2012Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
10900000 shares
CY2012Q1 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
8.10
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
83000000
CY2010Q4 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
600000
CY2010Q4 nbix Subleased Agreement Area
SubleasedAgreementArea
16000 sqft
CY2010Q4 nbix Sublease Term
SubleaseTerm
P3Y
CY2012Q3 nbix Subleased Agreement Area
SubleasedAgreementArea
17000 sqft
CY2007 us-gaap Sale Leaseback Transaction Lease Terms
SaleLeasebackTransactionLeaseTerms
The Company entered into a lease agreement (Lease) with DMH Campus Investors, LLC (DMH) whereby it leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building.
CY2007 us-gaap Proceeds From Sale Of Real Estate
ProceedsFromSaleOfRealEstate
61000000
CY2007 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2007 nbix Property Plant Equipment Selling Price
PropertyPlantEquipmentSellingPrice
109000000
CY2007 nbix Mortgage Loans Assumed By Purchaser
MortgageLoansAssumedByPurchaser
47700000
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66342000 shares
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2300000 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2012Q3 us-gaap Licenses Revenue
LicensesRevenue
7988000
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2012Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
162000
CY2012Q3 us-gaap Investment Income Net
InvestmentIncomeNet
123000
CY2012Q3 us-gaap Revenues
Revenues
9357000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2916000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3962000
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
884000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-3078000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3324000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
13319000
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1400000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9860000
CY2012Q3 nbix Potential Dilutive Securities That Could Be Included In Computation Of Earnings Per Share Amount
PotentialDilutiveSecuritiesThatCouldBeIncludedInComputationOfEarningsPerShareAmount
1300000 shares
CY2012Q3 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
759000
CY2012Q3 nbix Sponsored Research And Development Revenue
SponsoredResearchAndDevelopmentRevenue
1369000
CY2012Q3 nbix Cease Use Expense
CeaseUseExpense
135000
CY2012Q3 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
64000
CY2012Q3 nbix Impact Of Sublease On Cease Use Charges
ImpactOfSubleaseOnCeaseUseCharges
150000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67199000 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2013Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
35000
CY2013Q3 us-gaap Investment Income Net
InvestmentIncomeNet
93000
CY2013Q3 us-gaap Licenses Revenue
LicensesRevenue
729000
CY2013Q3 us-gaap Revenues
Revenues
729000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11096000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12006000
CY2013Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
6000
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
875000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-11131000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3245000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
12735000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1700000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9490000
CY2013Q3 nbix Potential Dilutive Securities That Could Be Included In Computation Of Earnings Per Share Amount
PotentialDilutiveSecuritiesThatCouldBeIncludedInComputationOfEarningsPerShareAmount
2500000 shares
CY2013Q3 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
781000
CY2013Q3 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
97000

Files In Submission

Name View Source Status
0001193125-13-416082-index-headers.html Edgar Link pending
0001193125-13-416082-index.html Edgar Link pending
0001193125-13-416082.txt Edgar Link pending
0001193125-13-416082-xbrl.zip Edgar Link pending
d588779d10q.htm Edgar Link pending
d588779dex311.htm Edgar Link pending
d588779dex312.htm Edgar Link pending
d588779dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
nbix-20130930.xml Edgar Link completed
nbix-20130930.xsd Edgar Link pending
nbix-20130930_cal.xml Edgar Link unprocessable
nbix-20130930_def.xml Edgar Link unprocessable
nbix-20130930_lab.xml Edgar Link unprocessable
nbix-20130930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending